Breaking News Instant updates and real-time market news.

JNJ

Johnson & Johnson

$113.07

0.33 (0.29%)

06:33
11/25/16
11/25
06:33
11/25/16
06:33

Johnson & Johnson: NICE reverses decision on CDF leukaemia drug after price drop

Hundreds of people could benefit as NICE decision means ibrutinib can come off the Cancer Drugs Fund and be routinely available to treat chronic lymphocytic leukaemia. Ibrutinib will be available as a routine option for an estimated 620 patients with chronic lymphocytic leukaemia who have had treatment before, or who have genetic changes - known as 17p deletion or TP53 mutation. An earlier recommendation by NICE did not recommend ibrutinib, also known as Imbruvica, for routine NHS use. However, following a reduction in price, the independent appraisal committee were able to approve the drug as cost effective. Reference Link

JNJ Johnson & Johnson
$113.07

0.33 (0.29%)

10/18/16
UBSW
10/18/16
NO CHANGE
Target $137
UBSW
Buy
Johnson & Johnson robust pipeline underappreciated, says UBS
UBS analyst Matt Miksic said the Johnson & Johnson pipeline remains robust and is underappreciated. The analyst said the recent launch of biosimilars removes uncertainty and should be positive for the stock. He also expects the additional deployment of the company's capital - to expand its pipeline through in-licensing, partnerships or mid-sized acquisitions - to be incremental to his Buy thesis. Miksic has a $137 price target on Johnson & Johnson shares.
10/19/16
LEER
10/19/16
NO CHANGE
Target $140
LEER
Outperform
Johnson & Johnson should be bought on weakness, says Leerink
Leerink analyst Danielle Antalffy believes the recent selloff in Johnson & Johnson's shares was overdone and would recommend buying on weakness. The analyst views the company as well-equipped to manage the inevitable Remicade headwind and continues to believe Johnson & Johnson can drive improving top-line growth in 2017. She reiterates an Outperform rating and $140 price target on the shares.
10/19/16
UBSW
10/19/16
NO CHANGE
Target $144
UBSW
Buy
Johnson & Johnson has potential upside from expanding pipeline, says UBS
UBS analyst Matt Miksic noted Johnson & Johnson delivered a solid quarter and said he believes there is upside to his Buy thesis. The analyst cited the company's expanding pipeline, capital allocation strategy, and contracting across its broad portfolio and patient assistance programs is expected to help mitigate pressure from biosimilar competition. Miksic reiterated his Buy rating and raised his price target to $144 from $137 on Johnson & Johnson shares.
11/09/16
RBCM
11/09/16
NO CHANGE
RBCM
Johnson & Johnson should be bought on recent weakness, says RBC Capital
After meeting with J&J's VP, Investor Relations, RBC Capital analyst Glenn Novarro says that the company's Q3 pharma results indicate that the growth of its major drugs can more than offset any declines in Remicade sales next year. The analyst quotes J&J as saying that it has not been using price hikes to increase its sales, and he thinks that the company's diverse business model will allow it to avoid being hurt by any regulatory pressures. He is upbeat on the company's efforts to increase its margins and notes that its medical device results have improved. Novarro keeps a $133 price target and an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

KMX

CarMax

$68.84

0.17 (0.25%)

, FINL

Finish Line

$9.22

-0.21 (-2.23%)

20:25
09/21/17
09/21
20:25
09/21/17
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KMX

CarMax

$68.84

0.17 (0.25%)

FINL

Finish Line

$9.22

-0.21 (-2.23%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Sep

  • 22

    Sep

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:47
09/21/17
09/21
18:47
09/21/17
18:47
Periodicals
HP Enterprise planning approximately 5,000 job cuts, Bloomberg reports »

In part of a broader…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

RP

RealPage

$39.35

-0.1 (-0.25%)

18:41
09/21/17
09/21
18:41
09/21/17
18:41
Hot Stocks
RealPage expects $3M-$4M of renter's insurance claims from hurricanes »

RealPage announced that a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HPE

HP Enterprise

$13.79

0.16 (1.17%)

18:39
09/21/17
09/21
18:39
09/21/17
18:39
Periodicals
Breaking Periodicals news story on HP Enterprise »

HP Enterprise planning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Dec

  • 11

    Dec

YUM

Yum! Brands

$76.48

0.11 (0.14%)

18:37
09/21/17
09/21
18:37
09/21/17
18:37
Conference/Events
Yum! Brands management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MAR

Marriott

$107.57

-0.12 (-0.11%)

18:32
09/21/17
09/21
18:32
09/21/17
18:32
Conference/Events
Marriott management to meet with JPMorgan »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

ESPGY

Esprit Holdings

$1.21

0.018 (1.51%)

18:29
09/21/17
09/21
18:29
09/21/17
18:29
Conference/Events
Esprit Holdings management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

BA

Boeing

$256.04

0.58 (0.23%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Hot Stocks
Boeing: Turkish Airlines announces intent to order 40 787-9 Dreamliners »

Boeing and Turkish…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

M

Macy's

$21.16

-0.32 (-1.49%)

18:18
09/21/17
09/21
18:18
09/21/17
18:18
Conference/Events
Macy's management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

  • 27

    Sep

TAHO

Tahoe Resources

$5.60

0.02 (0.36%)

18:12
09/21/17
09/21
18:12
09/21/17
18:12
Hot Stocks
Tahoe Resources raises 2017 gold operations view to 400K-500K »

Tahoe Resources updated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ATKR

Atkore

$18.42

0.02 (0.11%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Conference/Events
Atkore management to meet with JPMorgan »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Sep

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

, TXN

Texas Instruments

$86.05

0.22 (0.26%)

18:11
09/21/17
09/21
18:11
09/21/17
18:11
Hot Stocks
On The Fly: After Hours Movers »

UP AFTER EARNINGS:…

YOGA

YogaWorks

$4.00

-0.04 (-0.99%)

TXN

Texas Instruments

$86.05

0.22 (0.26%)

PSDO

Presidio

$13.95

-0.06 (-0.43%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 21

    Sep

FTR

Frontier Communications

$11.69

-0.31 (-2.58%)

18:10
09/21/17
09/21
18:10
09/21/17
18:10
Hot Stocks
Frontier Communications operations in Florida return to near-normal levels »

Daily operations for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PLYA

Playa Hotels & Resorts

$10.66

-0.06 (-0.56%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Playa Hotels & Resorts reports no significant damage from Maria »

Playa Hotels &…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

, VSAR

Versartis

$21.60

-0.25 (-1.14%)

18:07
09/21/17
09/21
18:07
09/21/17
18:07
Hot Stocks
Ascendis spikes higher after Versartis Velocity trial fails to meet endpoint »

Shares of Ascendis Pharma…

ASND

Ascendis Pharma

$27.74

-1.55 (-5.29%)

VSAR

Versartis

$21.60

-0.25 (-1.14%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CE

Celanese

$103.90

-0.04 (-0.04%)

18:04
09/21/17
09/21
18:04
09/21/17
18:04
Hot Stocks
Celanese increases price of acetyl intermediates »

Celanese will increase…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DNOW

NOW Inc.

$12.98

0.1 (0.78%)

18:03
09/21/17
09/21
18:03
09/21/17
18:03
Conference/Events
NOW Inc. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

  • 01

    Nov

JOBS

51job

$58.50

0.01 (0.02%)

18:02
09/21/17
09/21
18:02
09/21/17
18:02
Hot Stocks
51job announces strategic investment in Lagou »

51job announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HES

Hess Corp.

$43.63

0.17 (0.39%)

17:53
09/21/17
09/21
17:53
09/21/17
17:53
Conference/Events
Hess Corp. management to meet with JPMorgan »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

  • 26

    Sep

  • 27

    Sep

APC

Anadarko

$48.49

3.68 (8.21%)

17:43
09/21/17
09/21
17:43
09/21/17
17:43
Recommendations
Anadarko analyst commentary at MUFG »

Anadarko buyback a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

HCC

Warrior Met Coal

$23.28

-1.05 (-4.32%)

17:42
09/21/17
09/21
17:42
09/21/17
17:42
Hot Stocks
Warrior Met Coal receives favorable IRS private letter ruling »

Warrior Met Coal reported…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MAA

MAA

$107.27

-0.03 (-0.03%)

17:35
09/21/17
09/21
17:35
09/21/17
17:35
Hot Stocks
MAA announces estimated impact of Hurricanes Irma and Harvey »

MAA announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NOC

Northrop Grumman

$280.42

0.38 (0.14%)

17:31
09/21/17
09/21
17:31
09/21/17
17:31
Hot Stocks
Northrop Grumman awarded $124.7M government contract »

Northrop Grumman Systems…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GD

General Dynamics

$205.72

1.45 (0.71%)

17:29
09/21/17
09/21
17:29
09/21/17
17:29
Hot Stocks
General Dynamics Electric Boat awarded $5B government contract »

General Dynamics Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAN

Aaron's

$38.83

-0.39 (-0.99%)

17:19
09/21/17
09/21
17:19
09/21/17
17:19
Hot Stocks
Aaron's provides update on impact of Hurricane Irma »

Aaron's plans to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.